US FDA Sapien XT approval 'worth the wait'
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences seems to have once again gained the upper hand over arch rival Medtronic in the transcatheter aortic valve implantation (TAVI) market, with the long-awaited US FDA approval of its next-generation Sapien XT valve.